Neuromodulatory efect of vardenafl on aluminium chloride/d‑galactose induced Alzheimer’s disease in rats: emphasis on amyloid‑beta, p‑tau, PI3K/Akt/p53 pathway, endoplasmic reticulum stress, and cellular senescence

dc.contributor.authorAwad, Heba H
dc.contributor.authorDesouky, Mahmoud A
dc.contributor.authorZidan, Alaa 
dc.contributor.authorBassem, Mariam 
dc.contributor.authorQasem, Amaal 
dc.contributor.authorFarouk, Mona 
dc.contributor.authorAlDeab, Haidy 
dc.contributor.authorFouad, Miral 
dc.contributor.authorHany, Cherry 
dc.contributor.authorBasem, Nada 
dc.contributor.authorNader, Rita 
dc.contributor.authorAlkalleny, Ashrakat 
dc.contributor.authorReda, Verina 
dc.contributor.authorGeorge, Mina Y
dc.date.accessioned2023-07-25T07:13:23Z
dc.date.available2023-07-25T07:13:23Z
dc.date.issued2023-07
dc.description.abstractDysregulation of protein homeostasis, proteostasis, is a distinctive hallmark of many neurodegenerative disorders and aging. Deleteriously, the accumulation of aberrant proteins in Alzheimer’s disease (AD) is accompanied with a marked collapse in proteostasis network. The current study explored the potential therapeutic efect of vardenafl (VAR), a phosphodiesterase-5 inhibitor, in AlCl3/d-galactose (d-gal)-induced AD in rats and its possible underlying mechanisms. The impact of VAR treatment on neurobehavioral function, hippocampal tissue architecture, and the activity of the cholinergic system main enzymes were assessed utilizing VAR at doses of 0.3 mg/kg and 1 mg/kg. Additionally, the expression level of amyloid-beta and phosphorylated tau proteins in the hippocampus were fgured out. Accordingly, VAR higher dose was selected to con- template the possible underlying mechanisms. Intriguingly, VAR elevated the cyclic guanosine monophosphate level in the hippocampus and averted the repressed proteasome activity by AlCl3/d-gal; hence, VAR might alleviate the burden of toxic protein aggregates in AD. In addition, a substantial reduction in the activating transcription factor 6-mediated endoplasmic reticulum stress was demonstrated with VAR treatment. Notably, VAR counteracted the AlCl3/d-gal-induced depletion of nuclear factor erythroid 2-related factor 2 level. Moreover, the anti-senescence activity of VAR was demonstrated via its ability to restore the balance of the redox circuit. The modulation of phosphatidylinositol-3-kinase/protein kinase B/p53 pathway and the reduction of nuclear factor kappa B level, the key regulator of senescence-associated secretory phenotype mediators release, with VAR treatment were also elucidated. Altogether, these fndings insinuate the possible therapeutic benefts of VAR in AD management.en_US
dc.identifier.otherhttps://doi.org/10.1007/s10787-023-01287-w
dc.identifier.urihttp://repository.msa.edu.eg/xmlui/handle/123456789/5641
dc.language.isoen_USen_US
dc.publisherSpringeren_US
dc.relation.ispartofseriesInfammopharmacology;
dc.titleNeuromodulatory efect of vardenafl on aluminium chloride/d‑galactose induced Alzheimer’s disease in rats: emphasis on amyloid‑beta, p‑tau, PI3K/Akt/p53 pathway, endoplasmic reticulum stress, and cellular senescenceen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
s10787-023-01287-w.pdf
Size:
4.39 MB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
51 B
Format:
Item-specific license agreed upon to submission
Description: